CompletedNot Applicable

Assessing Diagnostic Methods for Invasive Fungal Disease in Lung Transplant Recipients

109 participantsStarted 2015-01-01

Plain-language summary

This study aims to assess the diagnostic performance of different tests, including metagenomic next-generation sequencing (mNGS), real-time PCR, galactomannan assay, and lateral-flow device tests, in detecting invasive fungal disease in lung transplant recipients using bronchoalveolar lavage fluid samples. The study is retrospective and cross-sectional in design.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult lung transplant recipients aged 18 years and older. * Suspected cases of invasive fungal infection (invasive pulmonary aspergillosis or -Pneumocystis jirovecii pneumonia) based on clinical symptoms, radiological findings, or microbiological evidence. * Able to provide sufficient bronchoalveolar lavage fluid (BALF) samples for diagnostic testing. Exclusion Criteria: * Patients with confirmed non-fungal infections. * Patients unable to provide adequate BALF samples for analysis. * Patients with severe comorbidities that prevent study participation or completion.

What they're measuring

Diagnostic Accuracy of mNGS for Invasive Pulmonary Aspergillosis and Pneumocystis jirovecii Pneumonia

Timeframe: From January 2015 to April 2023

Trial details

NCT IDNCT06654076

SponsorGuangzhou Institute of Respiratory Disease

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-04-30

View on ClinicalTrials.gov More Invasive Fungal Disease trials